EKOS is a safe, repeatable and reliable treatment that dissolves thrombus quickly with low lytic, low blood loss and low trauma – resulting in proven long-term outcomes. EKOS leverages the power of targeted ultrasonic waves to thin and separate fibrin strands and accelerates lytic dispersion deeper into the clot. Backed by long-term data, EKOS is the first choice, smart choice, and right choice.
Ultrasonic Core Technology
- Minimally invasive, 15-minute procedure that is quick to perform
- Lytic agent: as low as 8 mg TPA used
- Ultrasonic waves accelerate clot dissolution by unwinding and thinning fibrin strands to expose more drug receptor sites; acoustic streaming drives the drug deeper into the clot for safe dissolution
Target Thrombus Safety
Acoustic Pulse Acceleration
Superior Clot Dissolution
Acoustic Pulse Thrombolysis
- Speeds time-to-clot dissolution.
- Results in quality clinical outcomes.
- Increases clot removal and enhances clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy.
- Requires significantly shorter treatment times compared to standard CDT.
Targets the Thrombus Safely
- Lowers the risk of bleeding and other complications.
- Dissolves clots without damaging vessels, valves or walls.
More Effective Drug Delivery
- Reduces dosage requirements by as much as 68% compared to standard, catheter-directed drug therapy.
- Requires up to 4x less drug dosage than traditional systemic delivery.
- Reduces RV/LV ratio with as little as 8mg total tPA used in combination with EKOS therapy.
Superior Clot Clearance
- 48% greater drug absorption within 1 hour.
- 84% greater drug absorption within 2 hours.
| Product Code | - |
| Application | Ultrasound-Assisted Catheter-Directed Thrombolysis |
| Manufacturer Country | USA |
| Guarantee Type | Based on manufacturer recommendations |